# Cisplatin+Pembrolizumab+RT in Vulvar Cancer

> **NCT04430699** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Vulvar Cancer
- Vulvar Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Pembrolizumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04430699
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-29
- **Primary completion:** 2026-04-30
- **Final completion:** 2028-01-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430699, "Cisplatin+Pembrolizumab+RT in Vulvar Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04430699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*